Cyrus Mozayeni follows ADC ‘beacon’ to Pheon CEO role; BeiGene loses business chief to Teva

Cyrus Mozayeni has been around the biotech business long enough not to be fazed when things don’t go as expected.

Soon after he closed his last startup in April, Vedere Bio II — a gene therapy biotech born out of another that was sold to Novartis — he returned to his network at Atlas Venture, where he is entrepreneur-in-residence, to scout new opportunities. Earlier this month, he started a new job as CEO of Pheon Therapeutics to replace Bertrand Damour at the Atlas-backed company.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Stakeholders weigh in on potential reforms to FDA advisory committee process

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 14, 2024

Hospital-based donor care linked to longer lung transplant survival rates

A new study by Penn researchers examined, for the first time, the differences in lung transplant graft outcomes from organs recovered from the two types

June 26, 2024

UQ study aims to reduce life-threatening allergic reactions in adolescents

A University of Queensland project aims to make the teenage years safer for Australian children diagnosed with life-threatening food allergies.

June 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.